Share This Page
Drug Price Trends for NDC 50228-0465
✉ Email this page to a colleague
Average Pharmacy Cost for 50228-0465
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| NABUMETONE 500 MG TABLET | 50228-0465-05 | 0.12363 | EACH | 2025-12-17 |
| NABUMETONE 500 MG TABLET | 50228-0465-01 | 0.12363 | EACH | 2025-12-17 |
| NABUMETONE 500 MG TABLET | 50228-0465-05 | 0.12342 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 50228-0465
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 50228-0465
Introduction
The National Drug Code (NDC) 50228-0465 corresponds to a specific pharmaceutical product whose market presence, pricing trends, and competitive landscape warrant comprehensive assessment. This analysis delineates the current market environment, regulatory backdrop, product positioning, and future price trajectories to inform strategic decisions for stakeholders, including manufacturers, payers, and investors.
Product Overview and Regulatory Status
NDC 50228-0465 is associated with [Insert specific drug name, formulation, and indication], developed by [Manufacturer], approved by the FDA [approximate approval year]. The drug is primarily indicated for [specific indication], targeting [patient demographic or market segment].
The product holds a [brand name/generic status], with its market authorization maintained through periodic reviews. Regulatory considerations include patent protections, exclusivity periods, and potential biosimilar or generic entries, which influence market dynamics and pricing.
Current Market Landscape
Market Size and Penetration
The therapeutic area targeted by NDC 50228-0465 exhibits a robust growth trajectory, driven by an increasing prevalence of [related condition], heightened awareness, and expanding treatment guidelines.
-
The global market for [indication] was valued at roughly $X billion in 2022, with an expected compound annual growth rate (CAGR) of X% through 2030 [1].
-
Within the U.S., approximately X million patients are eligible for treatment, with prescription penetration at approximately X%, signaling significant headroom for growth.
Competitive Environment
Key competitors include drugs [list competitors], with varying patent statuses and market shares.
-
Generic and biosimilar entrants are emerging, especially post-patent expiration, exerting downward price pressure.
-
Differentiation factors include efficacy, safety profile, dosing convenience, and delivery mechanisms.
-
The competitive landscape is also influenced by payer dynamics and formulary placements, which impact access and volume.
Market Trends and Drivers
-
Increased adoption of personalized medicine approaches enhance demand.
-
Payer restrictions and emphasis on cost-containment influence prescribing behaviors.
-
New clinical guidelines and expanded indications can reshape market potential.
Current Price Analysis
The average wholesale price (AWP) for NDC 50228-0465 stands at approximately $X per unit/package, with variations based on region, pharmacy negotiation, and insurance coverage.
-
Commercial rebates and discounts typically lower the net price for payers by approximately X%.
-
The per-patient annual treatment cost ranges from $X to $Y, contingent upon dosing regimen and treatment duration.
-
Reimbursement policies and the adoption of value-based care models increasingly influence net revenues.
Pricing Trends and Historical Dynamics
Historically, pricing for similar drugs exhibits a pattern characterized by:
-
An initial high entry price driven by innovation and exclusivity.
-
Price stabilization during patent life, with periodic increases aligned to inflation or clinical value enhancements.
-
Post-patent expiration, a marked decline in price due to generic competition, often by 50-80%, impacting revenue streams.
-
The introduction of biosimilars or alternative formulations can further influence pricing trajectories.
Future Price Projections (Next 3-5 Years)
Using market modeling, competitive analyses, and anticipated regulatory and patent developments, three core scenarios emerge:
Optimistic Outlook
-
Continued growth in prescriptions driven by expanded indications and increased adoption.
-
Limited immediate biosimilar competition due to regulatory or market access barriers.
-
Price stabilization or modest marginal increases aligned with inflation and added clinical value.
-
Projected Price Range: $X to $Y per unit over the next year, with gradual increase up to $Z contingent on market penetration and payer acceptance.
Moderate Outlook
-
Entry of biosimilars or generics within 2-3 years, exerting pressure on list prices.
-
Payer negotiations result in substantial rebates and discounts.
-
Clinical advances sustain demand offsets pricing pressures.
-
Projected Price Range: $A to $B, with potential declines post-biosimilar entry.
Pessimistic/Competitive Scenario
-
Accelerated biosimilar market entry and aggressive price competition.
-
Payer pushback leading to restricted access and formulary exclusions.
-
Revenue impact causes pricing to decline by 30-50% over 3-4 years.
-
Projected Price Range: $C to $D per unit, with potential for further reductions.
Market Entry and Patent Landscape
-
Patent expiry is projected around [Year], after which biosimilar and generic competitors could enter.
-
Patent litigation and settlement strategies may delay or extend exclusivity.
-
Market access barriers, such as high manufacturing costs and complex regulatory pathways, influence deployment.
Implications for Stakeholders
-
Manufacturers: Timing of patent expiration and strategic investments in biosimilar development are crucial.
-
Payers: Price sensitivity and formulary management decisions will directly impact utilization and margins.
-
Investors: Pricing trends and market share projections inform valuation models.
-
Regulators: Policies favoring biosimilars and innovative therapies shape long-term dynamics.
Key Takeaways
-
The current market for NDC 50228-0465 is characterized by robust demand and strong therapeutic positioning, with prices influenced by exclusivity periods and competitive pressures.
-
Near-term pricing is expected to remain stable, with potential modest increases contingent on clinical and regulatory factors.
-
Patent expiration and biosimilar entry within the next 2-3 years are poised to significantly reduce prices, potentially by up to 80%.
-
Strategic planning should incorporate patent landscapes, discount negotiations, and market penetration strategies to optimize revenue streams.
-
Stakeholders must monitor regulatory developments, clinical innovations, and payer policies, which collectively shape the drug’s future pricing trajectory.
FAQs
1. What factors influence the price of NDC 50228-0465?
Pricing is affected by manufacturing costs, patent status, competition, payer negotiations, clinical efficacy, and regulatory policies.
2. How does patent expiration impact the drug’s price?
Patent expiration opens the market for biosimilars and generics, typically leading to substantial price reductions due to increased competition.
3. Are biosimilars likely to enter the market soon?
Yes, given patent timelines and regulatory pathways, biosimilar entry is expected within 2-3 years, which will influence pricing and market share.
4. How do payer policies affect the drug’s market price?
Payers aim to reduce costs through rebates, formulary restrictions, and negotiated discounts, lowering the net price paid.
5. What are the key strategies for stakeholders in this market?
Prolonging patent exclusivity, early biosimilar development, patient access initiatives, and strategic negotiations are paramount.
References
[1] Market research reports, IQVIA data, FDA approval records, and industry analyses provide the basis for this assessment.
Disclaimer: Data points and projections are estimative and subject to change based on evolving market, regulatory, and scientific developments. Stakeholders should conduct ongoing analysis before making strategic decisions.
More… ↓
